These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2004-002358-72 Preoperative combined radiochemotherapy for patients with newly diagnosed, primary operable and locally advanced rectal carcinoma (cT3, Nx, M0) of the lower and middle rectum 2013-12-19 due-trials
Not reported 2005-003740-62 Preoperative chemoradiation with capecitabine and cetuximab within a multidisciplinary therapeutic approach in patients with operable T3-T4 rectal cancer: a phase II study 2011-11-09 due-trials
Ongoing 2007-002061-12 A randomized phase III study Comparing biweekly and tailored epirubicin + cyclophosphamide followed by biweekly tailored docetaxel (dtEC -- dtT)(A-arm) versus three weekly epirubicin + cyclophosphamid... not-yet-due
Not reported Terminated 2007-006750-26 Preoperative combined RadioChemo-MolecularTargetedTherapie (RC-MTTx) of the locally advanced rectal carcinoma (cT3NxM0) – a phase II pilot study with preoperative application of capecitabine (Xeloda),... 2009-02-27 due-trials
Reported results Terminated 2009-009874-28 Epirubicine plus Cyclophosphamid followed by Docetaxel +/- Sunitinib before surgery for the treatment of patients with HER2neu-negative operable breast cancer 2010-03-16 due-trials
Not reported 2010-023324-25 Multicentre randomized phase II study of neoadjuvant trastuzumab plus docetaxel with and without bevacizumab and trastuzumab plus docetaxel plus non-pegylated liposome-encapsulated doxorubicin (NPLD) ... 2014-04-16 due-trials
Ongoing, reported early 2010-024216-34 Neoadjuvant Endocrine Treatment +/- Bevacizumab in postmenopausal Patients with Operable Primary, HER2-neu negative Breast Cancer (including Lobular Cancer) (I) not suitable for Chemotherapy or (II) u... not-yet-due
Not reported 2010-024354-11 Preoperative induction chemotherapy in combination with Bevacizumab followed by combined chemoradiotherapy in locally advanced rectal cancer with high risk of recurrence- phase II pilot study with pre... 2013-08-26 due-trials
Not reported Terminated 2011-001010-34 A randomized, placebo-controlled, double-blind multicenter phase II study to investigate the protectivity and efficacy of Metformin against steatosis in combination with FOLFIRI and Cetuximab in subje... 2013-11-05 due-trials
Not reported 2011-004822-85 A prospective, open, randomized, phase-II study of a therapeutic cancer vaccine (L-BLP25, Stimuvax®) in the pre-operative treatment of women with primary breast cancer 2017-05-12 due-trials
Completed, report not yet due 2012-000265-20 A perioperative, single-arm multicenter Phase II academic trial to investigate the efficacy and safety of panitumumab in combination with irinotecan/5-fluorouracil/leucovorin (FOLFIRI) in patients wit... 2020-05-15 not-yet-due
Ongoing 2012-001850-24 A prospective randomized phase II trial of FOLFIRINOX alone versus FOLFIRINOX followed by radiochemotherapy in patients with locally advanced, primarily inoperable pancreatic cancer not-yet-due
Not reported 2013-000639-29 A prospective, open, randomized, academic phase II, two-arm trial evaluating the effect of fibrin-coated collagen (TachoSil®) on postoperative pancreatic leakage and fistula formation from the pancrea... 2017-02-20 due-trials
Reported results Terminated 2013-001028-21 P01 - A prospective, randomized, multicenter trial of additional radiochemotherapy to neoadjuvant chemotherapy in patients with locally advanced pancreatic adenocarcinoma 2015-03-12 due-trials
Ongoing 2016-004384-39 A prospective, open, randomized, phase II study of carboplatin/olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive hom... not-yet-due
Ongoing 2017-002505-35 BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mu... not-yet-due
Ongoing 2019-002364-27 An open-label, two-arm, randomized, single-stage phase II study of ATezolizumab in combination with dual HER2 blockade plus epirubicin as NEoadjuvant therapy for HER2-positive early breast cancer not-yet-due